Cancer Family
Connective and Soft Tissue Neoplasm
CI-CAN-00000010Explore in graph →
Non-malignant848 active trials17 approved drugs339 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000010Explore in graph →
Clinical trials
3,877 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06021626 | A Study of CRD3874-SI in People With Solid Tumors | recruiting | Phase 1 | 81 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06176989 | Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors | recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06798363 |
| Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma |
| recruiting |
| Phase 2 / Phase 3 |
| 32 |
| West China HospitalOTHER |
| 1 |
| Sep 21, 2026 |
| clinicaltrials |
| NCT06804655 | Pharmacoscopy for Patients With Refractory Primary Brain Tumors(EViDENCE-BT) | recruiting | Phase 2 | 40 | University of ZurichOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06898203 | Precision Imaging to Evaluate Kaposi Sarcoma(PRIME-KS) | recruiting | N/A | 180 | Washington University School of MedicineOTHER | 2 | Sep 21, 2026 | clinicaltrials |
| NCT07298083 | DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins | recruiting | — | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07705334 | A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors(Luca-1) | recruiting | Phase 1 | 30 | SHY TherapeuticsINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07810920 | Artificial Intelligence Into Ultrasound Diagnostics in Reproductive Medicine(AUDRIE) | recruiting | — | 1,600 | Semmelweis UniversityOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT00874874 | Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery(AngioNext) | completed | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04425967 | Short Course Of Preoperative Radiotherapy in Head and Neck-, Trunk- and Extremity Soft Tissue Sarcomas(SCOPES) | active not recruiting | N/A | 168 | The Netherlands Cancer InstituteOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04457258 | 68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma | active not recruiting | Early Phase 1 | 18 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04902443 | Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV | recruiting | Phase 1 | 58 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05252585 | A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) | active not recruiting | Phase 4 | 4 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05264974 | Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization | suspended | Phase 1 | 18 | University of FloridaOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05694871 | Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma | active not recruiting | Phase 2 | 77 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06025747 | A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for Liposarcomas | recruiting | Phase 1 | 18 | University of WashingtonOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06395103 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | recruiting | Phase 1 / Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 23 | Sep 17, 2026 | clinicaltrials |
| NCT06789666 | Digital Art Therapy for Young Cancer Survivors | recruiting | N/A | 15 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07297667 | GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours | recruiting | Phase 1 | 30 | Canadian Cancer Trials GroupNETWORK | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | not yet recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07695311 | EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT | not yet recruiting | Phase 1 | 24 | Rabi HannaOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07823985 | Preoperative Embolization for Highly Vascular Brain Tumors | not yet recruiting | N/A | 55 | Assiut UniversityOTHER | 0 | Sep 17, 2026 | clinicaltrials |
| NCT00050752 | Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer | recruiting | — | 1,130 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04273061 | Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity(CAPTIV-8) | recruiting | Phase 2 | 50 | British Columbia Cancer AgencyOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06843967 | A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma | recruiting | Phase 1 / Phase 2 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07297160 | CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors(CALySSEY) | withdrawn | Phase 1 | 0 | Baylor College of MedicineOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07823491 | Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall | not yet recruiting | Phase 3 | 228 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT03602092 | Observational Registry Data on GIST Patients | completed | — | 966 | National Health Research Institutes, TaiwanOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04104529 | Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department(BCB RIV) | recruiting | N/A | 350 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07056946 | Supra Inguinal Fascia Iliaca Block Versus Ultrasound-guided Caudal Analgesia for Pediatrics Undergoing Anterior and Lateral Thigh Surgeries: A Randomized Controlled Trial | completed | N/A | 70 | National Cancer Institute, EgyptOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07170644 | A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF) | active not recruiting | Phase 2 | 20 | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07802652 | Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma(IMMUSARC-7012) | not yet recruiting | Phase 2 | 80 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07819838 | Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations | not yet recruiting | Phase 1 / Phase 2 | 77 | Children's Oncology GroupNETWORK | 0 | Sep 15, 2026 | clinicaltrials |
| NCT07820033 | Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial(PEARL RCT) | not yet recruiting | Phase 2 | 46 | University Health Network, TorontoOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03307616 | Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery | active not recruiting | Phase 2 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03819985 | Shorter Course, Hypofractionated Pre-Surgery Radiation Therapy in Treating Patients With Localized, Resectable Soft Tissue Sarcoma of the Extremity of Superficial Trunk | active not recruiting | Phase 2 | 122 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04140526 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC(PRESERVE-001) | active not recruiting | Phase 1 / Phase 2 | 733 | OncoC4, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT04438824 | Palbociclib and INCMGA00012 in People With Advanced Liposarcoma | active not recruiting | Phase 2 | 42 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04751409 | Evaluating the Impact of Limited Compared With Intense Post-Operative Surveillance on Patient-Reported Outcomes in Patients With Stage II-III Soft Tissue Sarcoma of the Trunk and Extremities | recruiting | Phase 2 | 227 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06674811 | Biomarkers of Resiliency In Childhood Cancer Surgery(BRICCS) | recruiting | — | 40 | Mayo ClinicOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07176689 | Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) | recruiting | Phase 4 | 50 | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyINDUSTRY | 6 | Sep 14, 2026 | clinicaltrials |
| NCT07817095 | SBRT Combined With Reduced-Dose Anthracycline Chemotherapy and Toripalimab as Neoadjuvant Therapy for Localized High-Risk Undifferentiated Pleomorphic Sarcoma(SPARK) | not yet recruiting | Phase 2 | 39 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01484236 | National Lymphangioleiomyomatosis Registry, France(RE-LAM-CE) | recruiting | — | 200 | Vincent COTTINOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05821231 | Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma(MEDISARC-SBRT) | completed | Phase 1 | 14 | Institut Claudius RegaudOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05979493 | QL Block in Laparoscopic Myomectomy | recruiting | Phase 4 | 80 | Joseph Findley MDOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06797999 | First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma(ADCElerate1) | recruiting | Phase 1 / Phase 2 | 270 | Adcendo ApSINDUSTRY | 5 | Sep 11, 2026 | clinicaltrials |
| NCT07062003 | Minibeam Radiation Therapy With Tungsten Slit Collimator for the Treatment of Recurrent or Metastatic Skin or Soft Tissue Tumors | recruiting | N/A | 60 | Mayo ClinicOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07215611 | Financial Toxicity in Patients With Resected Soft Tissue and Bone Sarcomas | recruiting | — | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT03180268 | Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery | recruiting | Phase 3 | 163 | NRG OncologyOTHER | 5 | Sep 10, 2026 | clinicaltrials |
| NCT04031677 | Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma(STRASS2) | recruiting | Phase 3 | 250 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 15 | Sep 10, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 21, 2026source: clinicaltrials